Moderators of the Impact of (Poly)Phenols Interventions on Psychomotor Functions and BDNF: Insights from Subgroup Analysis and Meta-Regression.
aging
antioxidant
brain functions
brain plasticity
cognition
psychomotor functions
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
19 Sep 2020
19 Sep 2020
Historique:
received:
11
08
2020
revised:
11
09
2020
accepted:
17
09
2020
entrez:
23
9
2020
pubmed:
24
9
2020
medline:
1
4
2021
Statut:
epublish
Résumé
Recent anti-aging interventions have shown contradictory impacts of (poly)phenols regarding the prevention of cognitive decline and maintenance of brain function. These discrepancies have been linked to between-study differences in supplementation protocols. This subgroup analysis and meta-regression aimed to (i) examine differential effects of moderator variables related to participant characteristics and supplementation protocols and (ii) identify practical recommendations to design effective (poly)phenol supplementation protocols for future anti-aging interventions. Multiple electronic databases (Web of Science; PubMed) searched for relevant intervention published from inception to July 2019. Using the PICOS criteria, a total of 4303 records were screened. Only high-quality studies ( The reviewed studies support the beneficial effect of (poly)phenols-rich supplementation on psychomotor functions (ES = -0.677, This review suggests that age group, gender, the used phenolic compounds, their human bioavailability rate, and the supplementation dose as the primary moderator variables relating to the beneficial effects of (poly)phenol consumption on cognitive and brain function in humans. Therefore, it seems more advantageous to start anti-aging (poly)phenol interventions in adults earlier in life using medium (≈500 mg) to high doses (≈1000 mg) of phenolic compounds, with at least medium bioavailability rate (≥9%).
Sections du résumé
BACKGROUND
BACKGROUND
Recent anti-aging interventions have shown contradictory impacts of (poly)phenols regarding the prevention of cognitive decline and maintenance of brain function. These discrepancies have been linked to between-study differences in supplementation protocols. This subgroup analysis and meta-regression aimed to (i) examine differential effects of moderator variables related to participant characteristics and supplementation protocols and (ii) identify practical recommendations to design effective (poly)phenol supplementation protocols for future anti-aging interventions.
METHODS
METHODS
Multiple electronic databases (Web of Science; PubMed) searched for relevant intervention published from inception to July 2019. Using the PICOS criteria, a total of 4303 records were screened. Only high-quality studies (
RESULTS
RESULTS
The reviewed studies support the beneficial effect of (poly)phenols-rich supplementation on psychomotor functions (ES = -0.677,
CONCLUSION
CONCLUSIONS
This review suggests that age group, gender, the used phenolic compounds, their human bioavailability rate, and the supplementation dose as the primary moderator variables relating to the beneficial effects of (poly)phenol consumption on cognitive and brain function in humans. Therefore, it seems more advantageous to start anti-aging (poly)phenol interventions in adults earlier in life using medium (≈500 mg) to high doses (≈1000 mg) of phenolic compounds, with at least medium bioavailability rate (≥9%).
Identifiants
pubmed: 32961777
pii: nu12092872
doi: 10.3390/nu12092872
pmc: PMC7551086
pii:
doi:
Substances chimiques
Brain-Derived Neurotrophic Factor
0
Polyphenols
0
BDNF protein, human
7171WSG8A2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4104-10
pubmed: 26150497
J Physiol Pharmacol. 2015 Dec;66(6):811-21
pubmed: 26769830
J Nutr. 2017 Sep;147(9):1686-1692
pubmed: 28794213
Med Sci Sports Exerc. 2009 Jan;41(1):3-13
pubmed: 19092709
Nutrients. 2017 Jul 26;9(8):
pubmed: 28933745
J Physiol. 2012 Dec 15;590(24):6297-305
pubmed: 22988140
Brain Res Brain Res Rev. 2004 May;45(2):104-14
pubmed: 15145621
Curr Neuropharmacol. 2017;15(4):562-594
pubmed: 27784225
Front Cell Neurosci. 2018 Apr 27;12:114
pubmed: 29755324
Neuroimage. 2018 Jul 1;174:177-190
pubmed: 29548848
J Clin Med. 2020 May 25;9(5):
pubmed: 32466148
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Nutr Rev. 2014 Jul;72(7):429-52
pubmed: 24828476
Arch Med Sci. 2015 Dec 10;11(6):1164-78
pubmed: 26788077
Genes Nutr. 2007 Dec;2(3):257-73
pubmed: 18850181
Am J Clin Nutr. 2015 Mar;101(3):538-48
pubmed: 25733639
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Nutrients. 2018 Jul 24;10(8):
pubmed: 30042362
J Neurovirol. 2002 Dec;8(6):474-9
pubmed: 12476342
J Altern Complement Med. 2018 Jul;24(7):725-732
pubmed: 29583015
Immunology. 2015 Jan 10;144(3):365-373
pubmed: 25580634
Int J Dev Neurosci. 2005 Dec;23(8):663-71
pubmed: 16298100
Antioxid Redox Signal. 2012 Dec 1;17(11):1590-609
pubmed: 22114878
J Clin Epidemiol. 1998 Dec;51(12):1235-41
pubmed: 10086815
Front Pharmacol. 2016 Feb 12;7:24
pubmed: 26903869
J Clin Med. 2020 Mar 19;9(3):
pubmed: 32204500
Br J Clin Pharmacol. 2013 Mar;75(3):716-27
pubmed: 22775434
Appl Physiol Nutr Metab. 2016 Dec;41(12):1225-1232
pubmed: 27849355
Nature. 2014 Jul 24;511(7510):405-7
pubmed: 25056047
Eur J Nutr. 2017 Dec;56(8):2621-2631
pubmed: 28429081
Biochem Biophys Res Commun. 2014 Feb 28;445(1):218-24
pubmed: 24508265
Ther Adv Chronic Dis. 2011 May;2(3):175-95
pubmed: 23251749
Trends Neurosci. 1991 Feb;14(2):60-7
pubmed: 1708538
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Nitric Oxide. 2006 Sep;15(2):93-102
pubmed: 16626982
Oxid Med Cell Longev. 2009 Nov-Dec;2(5):270-8
pubmed: 20716914
Menopause. 2003 May-Jun;10(3):196-202
pubmed: 12792289
J Int Soc Sports Nutr. 2019 Mar 21;16(1):13
pubmed: 30898134
Psychopharmacology (Berl). 2018 May;235(5):1497-1511
pubmed: 29502273
J Neurosci. 2014 Jun 4;34(23):7862-70
pubmed: 24899709
Am J Clin Nutr. 2010 Jun;91(6):1590-7
pubmed: 20357044
Front Neurosci. 2018 Oct 23;12:721
pubmed: 30405328
Psychopharmacology (Berl). 2001 Oct;157(4):430-6
pubmed: 11605103
Clin Interv Aging. 2007;2(3):377-87
pubmed: 18044188
Nutrients. 2018 May 23;10(6):
pubmed: 29882843
Dialogues Clin Neurosci. 2002 Jun;4(2):197-210
pubmed: 22033483
Oxid Med Cell Longev. 2012;2012:914273
pubmed: 22701758
Phys Ther. 2003 Aug;83(8):713-21
pubmed: 12882612
Food Res Int. 2017 Sep;99(Pt 1):72-83
pubmed: 28784536
Eur Heart J. 2014 Apr;35(14):888-94
pubmed: 24357508
J Cardiovasc Pharmacol. 2006;47 Suppl 2:S215-20
pubmed: 16794461
J Clin Epidemiol. 2011 Jun;64(6):594-601
pubmed: 21144705
Int J Mol Sci. 2018 Sep 05;19(9):
pubmed: 30189583
Oxid Med Cell Longev. 2010 Jul-Aug;3(4):228-37
pubmed: 20972369
Appl Physiol Nutr Metab. 2017 Jul;42(7):773-779
pubmed: 28249119
Front Aging Neurosci. 2017 Sep 04;9:283
pubmed: 28928653
Br J Clin Pharmacol. 2013 Mar;75(3):588-602
pubmed: 22897361
Neurobiol Aging. 2002 Sep-Oct;23(5):795-807
pubmed: 12392783
J Altern Complement Med. 2000 Jun;6(3):219-29
pubmed: 10890330
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Front Nutr. 2018 Sep 21;5:87
pubmed: 30298133
BMC Nephrol. 2011 Oct 26;12:59
pubmed: 22029620
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Front Pharmacol. 2015 May 20;6:93
pubmed: 26042037
Eur J Neurol. 2019 Dec;26(12):1426-1432
pubmed: 31002206